- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01553175
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors
Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.
Study Overview
Status
Detailed Description
OBJECTIVES:
- To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
- To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
- To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression.
- To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors.
- To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples.
OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
DISEASE CHARACTERISTICS:
- Tumor samples from patients diagnosed with rhabdoid tumors
- Matched frozen tumor tissue from BRG1-negative tumors (preferred) or matched genomic DNA from tumors, 100 ng per tumor from BRG1-negative tumors
- Any source of DNA from BRG1-negative tumors (tumors, blood, etc.)
- Matched frozen tumor tissue from BRM-negative tumors to confirm that BRM is not mutated or altered but rather epigenetically suppressed when lost in rhabdoid tumors
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Absence or presence BRG1 and BRM expression in rhabdoid tumors
|
Mechanism of suppression of BRG1 and BRM genes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Reisman, MD, PhD, University of Florida
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AREN12B5
- COG-AREN12B5 (Other Identifier: Children's Oncology Group)
- CDR0000728521 (Other Identifier: Clinical Trials.gov)
- NCI-2012-00705 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Cancer
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnKidney/Urinary Cancer
-
PfizerCompletedKidney Cancer | Kidney Neoplasms | Renal Cell Carcinoma | Renal Cancer | Renal Cell Cancer | Cancer of the Kidney | Cancer of KidneyFinland
-
Tianjin Medical University Second HospitalRecruiting
-
Tianjin Medical University Second HospitalRecruiting
-
Cedars-Sinai Medical CenterRecruitingProstate Cancer Stage II | Prostate Cancer Stage I | Bladder Cancer Stage II | Kidney Cancer Stage IUnited States
-
Dana-Farber Cancer InstituteCompletedKidney Cancer | Prostate Cancer | Genitourinary CancerUnited States
-
Intuitive SurgicalCompleted
-
University of Texas Southwestern Medical CenterCompletedKidney Cancer | Kidney Cancer Metastatic | Kidney Cancer, Stage IVUnited States
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
Clinical Trials on gene expression analysis
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupCompleted
-
Renmin Hospital of Wuhan UniversityNot yet recruitingStage III Colorectal CancerChina
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
The Christie NHS Foundation TrustUnknownSarcoma | Cervical Cancer | Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Prostate Cancer | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer | Primary Peritoneal Cavity CancerUnited Kingdom
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)UnknownOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruiting